Advertisement News Archives - Page 724 of 5208 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 23, 2026

AstraZeneca’s Calquence plus venetoclax gains approval in US to treat CLL

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the first-line setting.

AstraZeneca’s Calquence plus venetoclax gains approval in US to treat CLL